Search results for: 'formulation components shift'

The market for healthcare services in Malaysia is less developed, with many clinical testing services being unavailable outside of cities. Unsubstantiated disease and unconfirmed mortality diagnoses are common in the country despite universal care, significant mixed investment in the local healthcare system, and health expenditure favourable to oth...

Frost & Sullivan has recently completed a comprehensive analysis on the current and future strategic imperatives of game-changing Asia-Pacific (APAC) pharmaceutical companies. The analysis primarily focuses on the changing trends in the pharmaceutical industry with respect to drug research and development, manufacturing, supply chain, and marketing...

This study provides a comprehensive analysis of the contract research and manufacturing services (CRAMS) segment in India by focusing on drug discovery to pre-clinical toxicology, Active Pharmaceutical Ingredient (API), Formulations and Injectables. The study is based on detailed primary research, and includes an evaluation of the market size as we...

The Asia-Pacific next-generation diagnostics market's revenue is projected to decline by 5.0% in 2023, attributed to the reduced demand for COVID-19-related testing. Rapid expansion in non-COVID molecular diagnostics and point-of-care testing (POCT) will not be sufficient to drive the overall recovery of the region. As companies continue to focus o...

19 Jun 2017  |  Asia Pacific  |  Market Research

Growth Opportunities in the APAC IVD Market, Forecast to 2021

Digital Pathology and Laboratory Automation are Two Strategic Themes Driving the Growth of the IVD Market

Infographics

×

The study aims to analyze and forecast the Asia Pacific (APAC) in-vitro diagnostics (IVD) market outlook and technology trends for 2016. Research Scope: • Key trends and opportunities in the IVD market, which has been segmented into 8 major divisions: o Immunochemistry o Self-monitoring Blood Glucose (SMBG) Meter o Hematology o Point-of-care T...

Clinical laboratories are an essential part of the health industry. Approximately 80% of physicians' diagnoses is estimated to be the result of laboratory tests. The constant pressure to reduce healthcare spending is shifting healthcare application in favor of the laboratory, making it a more valuable part of the treatment plan. Vietnam CLT marke...

10 Jan 2018  |  Asia Pacific  |  Market Research

APAC Biosimilar Market, Forecast 2025

Patent Expiries, Defined Regulatory Pathways, and Escalating Healthcare Costs to Boost Growth

Infographics

×

Key Issues Addressed Key Benefits

Biosimilars is a massive opportunity; regardless of a slow start, the market will eventually be a huge business. As per Frost & Sullivan’s estimate, biologic drugs worth $70–$80 billion will lose exclusivity in the next 5 years globally and APAC’s contribution would be more than 20%. Countries in the region, such as India, China, and South Korea, o...